Abstract
The subclassification of α- and β-adrenoceptors has resulted in many opportunities for drug discovery. Important adrenoceptor targets include β2-agonists as bronchodilators, β1 or β1/β2 antagonists as antihypertensives, centrally acting α2-agonists for a variety of applications and α1-antagonists for hypertension and benign prostatic hyperplasia. The pharmacology and nomenclature of 9 adrenoceptors is now established, with α1, α2 and β-adrenoceptors being divided into three subtypes each. It is unlikely that additional discrete adrenoceptor sequences will be identified; however the presence of “affinity states” can give rise to tissue specific differences in pharmacology for a specific subtype. Polymorphisms and splice variants of adrenoceptors continue to be identified; in some cases these modifications can affect pharmacological characteristics and could influence the efficacy of adrenoceptor-targeted therapy. Selective antagonists are now available of all 9 adrenoceptor subtypes. Although these will not all have therapeutic application, the availability of improved pharmacologic tools could lead to the identification of new adrenoceptor targets.
Keywords: Uroselectivity, receptor polymorphism, splice variant, α1L-adrenoceptor, β4-adrenoceptor
Current Topics in Medicinal Chemistry
Title: Subclassification and Nomenclature of α- and β-Adrenoceptors
Volume: 7 Issue: 2
Author(s): J. Paul Hieble
Affiliation:
Keywords: Uroselectivity, receptor polymorphism, splice variant, α1L-adrenoceptor, β4-adrenoceptor
Abstract: The subclassification of α- and β-adrenoceptors has resulted in many opportunities for drug discovery. Important adrenoceptor targets include β2-agonists as bronchodilators, β1 or β1/β2 antagonists as antihypertensives, centrally acting α2-agonists for a variety of applications and α1-antagonists for hypertension and benign prostatic hyperplasia. The pharmacology and nomenclature of 9 adrenoceptors is now established, with α1, α2 and β-adrenoceptors being divided into three subtypes each. It is unlikely that additional discrete adrenoceptor sequences will be identified; however the presence of “affinity states” can give rise to tissue specific differences in pharmacology for a specific subtype. Polymorphisms and splice variants of adrenoceptors continue to be identified; in some cases these modifications can affect pharmacological characteristics and could influence the efficacy of adrenoceptor-targeted therapy. Selective antagonists are now available of all 9 adrenoceptor subtypes. Although these will not all have therapeutic application, the availability of improved pharmacologic tools could lead to the identification of new adrenoceptor targets.
Export Options
About this article
Cite this article as:
Hieble J. Paul, Subclassification and Nomenclature of α- and β-Adrenoceptors, Current Topics in Medicinal Chemistry 2007; 7 (2) . https://dx.doi.org/10.2174/156802607779318172
DOI https://dx.doi.org/10.2174/156802607779318172 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Ultrasonography of Peripheral Entheses in the Diagnosis and Assessment of Spondyloarthropathies
Current Rheumatology Reviews New Anti-Angiogenic Targeted Therapy in Advanced Renal Cell Carcinoma (RCC):Current Status and Future Prospects
Reviews on Recent Clinical Trials Role of the heme oxygenase-adiponectin-atrial natriuretic peptide axis in renal function
Current Pharmaceutical Design Leptin and the Ob-Receptor as Anti-Obesity Target: Recent In Silico Advances in the Comprehension of the Protein-Protein Interaction and Rational Drug Design of Anti- Obesity Lead Compounds
Current Pharmaceutical Design A Retrospective Study on the Incidence of Seizures among Neurosurgical Patients Who Treated with Imipenem/Cilastatin or Meropenem
Current Pharmaceutical Biotechnology Structural Alterations of the Retinal Microcirculation in the “Prehypertensive” High- Normal Blood Pressure State
Current Pharmaceutical Design Cardiometabolic Risk Related to the Association of hypertriglyceridemia-Low HDLc
Current Pharmaceutical Design Hypotensive Effects of the Triterpene Oleanolic Acid for Cardiovascular Prevention
Current Molecular Pharmacology Causes and Effects of Cellular Oxidative Stress as a Result of MDMA Abuse
Current Pharmaceutical Biotechnology May Endocrine Therapy be Associated with Cognitive Impairment in Breast Cancer Patients?
Clinical Cancer Drugs Medical Treatment Of Elderly Patients With Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Graphical Abstracts
Letters in Drug Design & Discovery Dysfunction of Pulmonary Vascular Endothelium in Chronic Obstructive Pulmonary Disease: Basic Considerations for Future Drug Development
Current Drug Metabolism Synthesis and Biological Evaluations of Novel Nitric Oxide-donating Derivatives of [1,2,4]triazol-5(4H)-one with N-phenylpyrrolyl-2-tetrazole Moiety as Anti-hypertension Candidates
Letters in Drug Design & Discovery The Efficacy and Safety of Cilnidipine on Mild to Moderate Essential Hypertension: A Systematic Review and Meta-analysis of Randomized Controlled Trials in Chinese Patients
Cardiovascular & Hematological Disorders-Drug Targets microRNA as Biomarkers and Regulator of Cardiovascular Development and Disease
Current Pharmaceutical Design The Effect of SEX/Gender on Cardiovascular Pharmacology
Current Pharmaceutical Design Fenofibrate: Metabolic and Pleiotropic Effects
Current Vascular Pharmacology Plasma Glucose Concentrations and Cardiac Hypertrophy in Essential Hypertension
Current Hypertension Reviews Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness
Current Neuropharmacology